Open AccessPost hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al.
Author(s) -
Ramires Felix J.A.,
Martinez Felipe,
Gómez Efraín A.,
Demacq Caroline,
Gimpelewicz Claudio R.,
Rouleau Jean L.,
Solomon Scott D.,
Swedberg Karl,
Zile Michael R.,
Packer Milton,
McMurray John J.V.
Publication year - 2018
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.12355
Subject(s) - ivabradine , medicine , heart failure , sacubitril , enalapril , cardiology , valsartan , cardiomyopathy , sacubitril, valsartan , post hoc analysis , heart rate , ejection fraction , angiotensin converting enzyme , blood pressure